WendyJoLevinMDMS

VP Clinical Development Fate Therapeutics

Dr. Levin is on Doximity

As a Doximity member you'll join over two million verified healthcare professionals in a private, secure network.

Gain access to free telehealth tools, such as our “call shielding” and one-way patient texting.
Connect with colleagues in the same hospital or clinic.
Read the latest clinical news, personalized to your specialty.

Office
10646 Science Center Dr
CB10
San Diego, CA 92121
Phone+1 858-622-8019

Fax+1 877-481-5208

University of WashingtonFellowship, Hematology and Medical Oncology, 2001 - 2004
University of Southern California/Los Angeles General Medical Center (USC/LA General)Residency, Internal Medicine, 1998 - 2001
St. George's University School of MedicineClass of 1998

PubMed

4 citations
First-In-Human Phase I Study of Tinengotinib (TT-00420), a Multiple Kinase Inhibitor, as a Single Agent in Patients With Advanced Solid Tumors.
Sarina A Piha-Paul, Binghe Xu, Ecaterina E Dumbrava, Siqing Fu, Daniel D Karp
The Oncologist. 2024-04-04
94 citations
Treatment with PF-04449913, an oral smoothened antagonist, in patients with myeloid malignancies: a phase 1 safety and pharmacokinetics study
Giovanni Martinelli, Vivian G. Oehler, Cristina Papayannidis, Rachel Courtney, Naveed Shaik
The Lancet. Haematology. 2015-08-01
57 citations
A Phase I Study of PF-04449913, an Oral Hedgehog Inhibitor, in Patients with Advanced Solid Tumors
Andrew J. Wagner, Wells A. Messersmith, Naveed Shaik, Sherry Li, Xianxian Zheng
Clinical Cancer Research. 2015-03-01

New Data Demonstrates Novel Genomic Technology Provides Ultra-Sensitive Detection of Gene Fusions from RNAOctober 18th, 2022
New California Law Increases Access to Biomarker Testing for Late-Stage Cancer PatientsOctober 13th, 2021
Winning the Race to Fight Lung Cancer? Medtech Company with RTP Lab Says It Can Speed up Biomarker Test at Lower CostsSeptember 8th, 2023
Join now to see all